VOLUME 28 1987

SUBJECT INDEX

Abstinence, 87
  fluid diet
  morphine
  physical dependence
Acceptability, 525
  amino acid analogues
  drinking
Acetylcholine concentration, 157
  ethylcholine aziridinium
  extinction
  learning and memory impairment
Acute exposure, 147
  central nervous system
  choline uptake
  noise
Adenosine receptors, 179
  caffeine
  locomotor activity
  L-phenylisopropyladenosine
  strain differences
Age differences, 341
  lighting
  individual housing
  phencyclidine
Aggression, 503
  dose-dependent effects
  monkeys
  tryptophan
Alcohol preference, 105
  ethanol
  selective breeding
  tolerance
Alpha-2 agonists, 283
  CNS depressants
  neuroleptics
  opioid antagonists
  opioid-induced rigidity
  reversal effects
  route of administration
Amino acid analogues, 525
  acceptability
  drinking
Amino acids, 15
  barrel rotation
  bradykinin analogs
  intracerebroventricular administration
  neuropeptides
Amphetamine
  apomorphine, 393
  ascorbic acid, 381
  behavioral effects, 423
  central cholinergic mechanisms, 335
  conditioned taste aversion, 335
  cue properties, 251
  differential involvement, 335
  dopaminergic/non-dopaminergic substrates, 251
  dopamine neuronal firing, 393
  drug interaction, 335
  electrical stimulation, 251
  haloperidol, 251
  investigatory behavior, 393
  in vivo voltammetry, 381
  locomotor activity, 393, 423
  morphine, 335
  serotonin depletion, 381
  stereotypy, 423
  uric acid, 381
  ventral tegmentum, 251
d-Amphetamine, 311
  brain stimulation reward
  drug interactions
  morphine
  threshold determination
Angiotensin II, 947
  insulin-induced drinking
  plasma volume
Animal model
  antidepressant-like profiles, 321
  cerebral embolization, 243
  discrimination task, 243
  drug interaction, 321
  escape failures, 321
  GABA agonists, 321
  learned helplessness, 321
  locomotor activity, 291
  memory impairment, 243
  MPTP pretreatment, 291
  nicotine, 291
  noradrenergic receptors, 321
  Parkinson's disease, 291
  swimming-induced immobility, 321
Antidepressant-like profiles, 321
  animal models
  drug interaction
  escape failures
  GABA agonists
  learned helplessness
  noradrenergic receptors
  swimming-induced immobility
Anxiogenic effects, 29
  light/dark test
  locomotor activity
  methyl-β-carboline-3-carboxylate
  RO 15-1788
Apomorphine
  amphetamine, 393
  climbing behavior, 35
  D1 binding sites, 477
  D2 binding sites, 477
  dopamine neuronal firing, 393
  dopamine receptor sensitivity, 35
  investigatory behavior, 393
  locomotor activity, 393
  stereotypy, 477
  up-regulation, 477
Apparatus
  radial arm maze, 157
  holeboard, 75
Arecoline, 275
  autoimmunity
  dose-dependent effects
  motor responses
  nicotine
  strain differences
Ascorbic acid, 381
  amphetamine
  in vivo voltammetry
  serotonin depletion
  uric acid
Atropine, 375
  chronic administration
  dose-dependent effects
  drug interactions
  key-pecking behavior
  physostigmine
  pigeons
Autoimmunity, 275
  arecoline
  dose-dependent effects
  motor responses
  nicotine
  strain differences
Autotomy, 385
  deafferentation
  beta-endorphin concentrations
  Met-enkephalin concentrations
  strain differences

Baboons, 389
  cocaine substitution procedure
  intravenous self-administration
  phenylpropanolamine
Barbiturates, 75
  benzodiazepine receptor agonist
  drug interaction
  exploratory activity
Barrel rotation, 15
  amino acids
  bradykinin analogs
  intracerebroventricular administration
  neuropeptides
Basal gastric acid secretion, 419
  gastric ulcers
  histidine carboxylase
  intraluminal pH levels
Behavioral analyses, 43
  drug interaction
  ethylketocyclazocine
  locomotor activity
  naloxone
Behavioral development, 411
  developmental toxicity
  perinatal phencyclidine
  prenatal phencyclidine
Behavioral effects
  amphetamine, 423
  dose-dependent effects, 153
  drug comparisons, 153
  N-ethyl-3,4-methylenedioxy-amphetamine, 153
  locomotor activity, 423
  stereotypy, 423
Behavioral hyperactivity, 469
  cerebral glucose metabolism
  choline supplementation
  chronic administration
  pentobarbital
Behavioral tolerance, 111
  chronic ethanol tolerance
  free-choice consumption
  selective breeding
Benzodiazepine receptor agonist, 75
  barbiturates

drug interaction
exploratory activity
Benzodiazepine receptor binding, 521
GABA
in vivo
Tyr-MIF-1
Benzodiazepine receptors, 21
brain stimulation, electrical
medial hypothalamus
Benzodiazepines
β-carbolines, 427
eating, 427
5-HT_{1A} agonists, 187
hypertonic saline consumption, 187
palatability, 427
rehydration, 187
Beta-adrenoceptors, 171
cardiovascular effects
chronic treatment
delta-9-tetrahydrocannabinol
Bradykinin analogs, 15
amino acids
barrel rotation
intracerebroventricular administration
neuropeptides
Brain
amygdala, 291
bicuculline, 21
caudate, 381, 423
dorsal hippocampus, 327
dorsal raphe nuclei, 327
frontal cortex, 147
globus pallidus, 381
hippocampus 147, 157, 465
hypothalamus, 147
lateral habenular nuclei, 327
lateral hypothalamus, 197, 511
medial amygdala, 101
median raphe nuclei, 327
midbrain central gray, 21
neostriatum, 453
nucleus accumbens, 423
olfactory tubercle, 291
prefrontal cortex, 327
striatum 35, 147, 291
substantia nigra pars reticulata, 453
ventral tegmentum, 251, 261
Brain stimulation, electrical, 21
benzodiazepine receptors
medial hypothalamus
Brain stimulation reward, 311
d-amphetamine
drug interactions
morphine
threshold determination

Caffeine, 179
adenosine receptors
locomotor activity
L-phenylisopropyladenosine
strain differences
Capsaicin, 65
route of administration
substance P release
thermoregulation
Tween 80
β-Carbolines, 427
benzodiazepines
eating
palatability
Cardiovascular effects, 171
beta-adrenoceptors
chronic treatment
delta-9-tetrahydrocannabinol
Cardiovascular responses, 459
cocaine
drug interaction
human studies, males
marijuana
Catalepsy, 453
GABA mechanism
muscle rigidity
substantia nigra pars reticulata
Central cholinergic mechanisms, 335
amphetamine
conditioned taste aversion
differential involvement
drug interaction
morphine
Central mechanism, 401
chronic administration
cocaine
discriminative stimulus properties
tolerance
Central nervous system, 147
acute exposure
choline uptake
noise
Cerebral embolization, 243
animal model for dementia
discrimination task
memory impairment
Cerebral glucose metabolism, 469
behavioral hyperactivity
choline supplementation
chronic administration
pentobarbital
Choline supplementation, 469
behavioral hyperactivity
cerebral glucose metabolism
chronic administration
pentobarbital
Choline uptake, 147
acute exposure
central nervous system
noise
Chronic administration
atropine, 375
behavioral hyperactivity, 469
central mechanism, 401
cerebral glucose metabolism, 469
choline supplementation, 469
cocaine, 401
discriminative stimulus properties, 401
dose-dependent effects, 375
drug interactions, 375
key-pecking behavior, 375
pentobarbital, 469
physostigmine, 375
pigeons, 375
tolerance, 401
Chronic ethanol tolerance, 111
behavioral tolerance
free-choice consumption
selective breeding
Chronic excessive intake, 517
cocaine
oral self-administration
schedule induction
Chronic treatment, 171
beta-adrenoceptors
cardiovascular effects
delta-9-tetrahydrocannabinol
Cigarette smoking, 305
human studies
nicotine intake
tobacco smoke refining
Classical conditioning, 7
nitrous oxide
skin conductance
Climbing behavior, 35
apomorphine
dopamine receptor sensitivity
CNS depressants, 283
alpha-2-agonists
neuroleptics
opioid antagonists
opioid-induced rigidity
reversal effects
route of administration
Cocaine
cardiovascular responses, 459
central mechanism, 401
chronic administration, 401
chronic excessive intake, 517
discriminative stimulus properties, 401
drug interaction, 459
human studies, male, 459
injection speed, 407
marijuana, 459
minimum reinforcing dose, 407
monkeys, crab-eating, 407
oral self-administration, 517
pentobarbital, 407
schedule induction, 517
self-administration, 407
tolerance, 401
Cocaine substitution procedure, 389
baboons
intravenous self-administration
phenylpropanolamine
Cognitive behavior, 213
human studies
methylphenidate
problem solving
Conditioned place preference
drug interaction, 267
lateral hypothalamus, 511
locomotor activity, 267
morphine, 267
naltrexone, 267
reinforcement, 511
substance P, 511
Conditioned taste aversion
amphetamine, 335
central cholinergic mechanisms, 335
differential involvement, 335
drug interaction, 219, 335
morphine, 219, 335
nicotine, 495
opiate antagonist, 219
opiate receptors, 219
place conditioning, 219
route of administration, 495
saccharin, 495
Cue properties
amphetamine, 251
differential effects, 261
discrimination, 261
dopaminergic/non-dopaminergic substrates, 251
electrical stimulation, 251, 261
haloperidol, 251
physostigmine, 261
ventral tegmentum, 251, 261

D1 binding sites, 477
  apomorphine
  D2 binding sites
  stereotypy
  up-regulation
D2 binding sites, 477
  apomorphine
  D1 binding sites
  stereotypy
  up-regulation
Deafferentation, 385
  autotomy
  beta-endorphin concentrations
  Met-enkephalin concentrations
  strain differences
Delayed onset, 203
  escape behavior
  haloperidol
  learning
Depressive behavior, 367
  desipramine
  neonatal exposure
  zimeldine
Desipramine, 367
  depressive behavior
  neonatal exposure
  zimeldine
Developmental toxicity, 411
  behavioral development
  perinatal phencyclidine
  prenatal phencyclidine
Diazepam
  extinction, 81
  free recall, 347
  human studies, 347
  memory, explicit, 347
  memory, implicit, 347
  monkeys, 81
  neurological impairment, 347
  self-administration, 81
  spared memory function, 347
  word completion, 347
Differential effects, 261
  cue properties
  discrimination
  electrical stimulation
  physostigmine
  ventral tegmentum
Differential involvement, 335
  amphetamine
  central cholinergic mechanisms
  conditioned taste aversion
  drug interaction
  morphine
Diisopropylphosphofluoridate, 317
  genetic variation
  inbred mice
  paraoxonase activity
2,5-Dimethoxy-4-methylamphetamine, 327
  dose-dependent effects
  hallucinogens
  intracranial administration
  operant behavior
Discrimination, 261
  cue properties
  differential effects
  electrical stimulation
  physostigmine
  ventral tegmentum
Discrimination task, 243
  animal model for dementia
  cerebral embolism
  memory impairment
Discriminative stimulus properties, 401
  central mechanism
  chronic administration
  cocaine
  tolerance
Dopamine neuronal firing, 393
  amphetamine
  apomorphine
  investigatory behavior
  locomotor activity
Dopamine receptor sensitivity, 35
  apomorphine, 35
  climbing behavior, 35
  hypothyroidism, 193
  post-synaptic changes, 193
Dopaminergic/non-dopaminergic substrates, 251
  amphetamine
  cue properties
  electrical stimulation
  haloperidol
  ventral tegmentum
Dose-dependent effects
  aggression, 503
  arecoline, 275
  atropine, 375
  autoimmunity, 275
  behavioral effects, 153
  chronic administration, 375
  2,5-dimethoxy-4-methylamphetamine, 327
  drug comparisons, 153
  drug interactions, 375
  N-ethyl-3,4-methylenedioxyamphetamine, 153
  hallucinogens, 327
  intracranial administration, 327
  key-pecking behavior, 375
  mephenytoin, 483
  methsuximide, 483
  monkeys, 503
  motor responses, 275
  nicotine, 275
  operant behavior, 327
  physostigmine, 375
  pigeons, 375, 483
  repeated acquisition, 483
  strain differences, 275
  tryptophan, 503
Drinking
  acceptability, 525
  amino acid analogues, 525
  ethanol, 437
  NaCl intake, 209
  repeated administration, 209
  reserpine, 209
  social structure, 437
  stress, 437
  tolerance, 209
Drug
  amphetamine 219, 251, 335, 381, 393, 423
  d-amphetamine, 311
  anti-dynorphin B antiserum, 465
  apomorphine 35, 393, 477
  arecoline, 275, 433
  atropine, 15, 335, 375, 433
  B4162, 15
  baclofen, 283
  bicuculline, 433
  buprenorphine, 283
  buspirone hydrochloride, 1
  caffeine, 179
  capsaicin, 65, 219
  captopril, 15
  carbidopa, 283
  chlomipramine, 385
  chlorazepate, 29
  p-chlorophenylalanine, 381
  m-chlorophenylpiperazine hydrochloride, 1
  choline, 469
  clonidine, 235, 443
  cocaine, 81, 389, 401, 407, 459, 517
  2-deoxy glucose, 71
  desipramine, 367
  dexamethasone, 443
  diazepam, 15, 75, 81, 283, 347
  diethyl ether, 283
  diisopropylphosphofluoridate, 317
  dimaprit, 283
  droperidol, 283
  ephedrine, 361
  ethanol, 53, 57, 75, 105, 111, 437
  ethylcholine aziridinium, 157
  ethylketocyclazocine, 43, 489
  fenfluramine, 1
  fentanyl, 283
  fluoxetine, 1
  flurothyl, 165
  FMHd, 419
  FMHm, 419
  gamma-acetylenic GABA, 283
  geprione, 187
  guanethidine, 283
  guanfacine, 283
  haloperidol, 15, 35, 175, 203, 251, 283, 423, 477
  6-hydroxydopamine, 197
  8-hydroxy-2(di-n-propylamine)-tetraline hydrobromide, 1
  idazoxan, 283
  imipramine, 321
  ipsapirone, 187
  3-isobutyl-1-methylxanthine, 235
  isoflurane, 283
  ketanserin, 353
  ketocyclazocine, 71
  kojic amine, 283
  lithium chloride, 219, 335
  marijuana, 459
  MDA, 39
  MDMA, 39
  mecamylamine, 275
  mephenytoin, 483
  metergoline, 1
  methadone, 87
  methohexital, 283
  5-methoxy-N-N-dimethyltryptamine hydrogen oxalate, 1
  methsuximide, 483
  methyl-atropine, 335
  methyl-β-carboline-3-carboxylate, 29
  3,4-methylenedioxymethamphetamine, 153
  N-methyl-3,4-methylenedioxyamphetamine, 153
  methylnaltrexone, 219
  methylphenidate, 213
  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 291
  methysergide, 283

methiamide, 283
mianserin, 353
midazolam, 21, 187, 427
MK-212, 433
monosodium glutamate, 165
morphine, 87, 95, 197, 219, 227, 267, 283, 311, 335
Mr2266, 227
Mr2267, 227
muscimol, 15, 321
naloxone, 15, 43, 87, 165, 227, 235
naltrexone, 95, 147, 219, 267
naltrexone methyl bromide, 283
nicotine, 275, 291, 305, 495
nitrous oxide, 7
noradrenaline, 101
8-OH-DPAT, 187
pancuronium, 283
penbutolol, 321
pentobarbital, 371, 407, 433, 469
phencyclidine, 341, 411, 489
phenobarbital, 15
phentolamine, 283
phenylephrine, 433
L-phenylisopropyladenosine, 179
phenylpropanolamine, 71, 389
phenytoin, 15
physostigmine, 261, 375
picrotoxin, 321, 443, 453
piperoxane, 283
pirenperone, 1, 39, 353
prazosin, 283, 321
progabide, 283, 443
reserpine, 209, 477
R16-6028, 427
RO 15-1788, 21,29
Ro 15-4513, 75
Ro 17-1812, 427
Ro23-0364, 187
SCH 23390, 477
scopolamine, 275
SKF 10,047, 489
sodium nitroprusside, 283
sodium pentobarbital, 75
sodium valproate, 47
suriclone, 427
Δ^9-tetrahydrocannabinol, 171
tetrahydro-β-carboline, 1
THIP, 21
1-(m-trifluoromethylphenyl)piperazinehydrochloride, 1
Tween 80, 65
U50,488, 227
zimeldine, 367
ZK 91296, 427
ZK 93423, 427
Drug comparisons, 153
  behavioral effects
  dose-dependent effects
  N-ethyl-3,4-methylenedioxyamphetamine
Drug discrimination
  5HT agonists, 1
  5HT receptors, 1
  pentobarbital, 371
  progesterone stimulus properties, 371
  sex differences, 371
  tetrahydro-β-carboline, 1
Drug interaction
  amphetamine, 335
  d-amphetamine, 311
  animal models, 321
  antidepressant-like profiles, 321
  atropine, 375
  barbiturates, 75
  behavioral analyses, 43
  benzodiazepine receptor agonists, 75
  brain stimulation reward, 311
  cardiovascular responses, 459
  central cholinergic mechanisms, 335
  chronic administration, 375
  cocaine, 459
  conditioned place preference, 267
  conditioned taste aversion, 219, 335
  differential involvement, 335
  dose-dependent effects, 375
  β-endorphin, 197
  escape failures, 321
  ethylketocyclazocine, 43, 489
  exploratory activity, 75
  fluoroethyl, 165
  GABA agonists, 321
  human studies, males, 459
  hypothermia, 165
  key-pecking behavior, 375
  lateral hypothalamus, 197
  learned helplessness, 321
  locomotor activity, 43, 267
  marijuana, 459
  MDA, 39
  MDMA, 39
  methylxanthines, 235
  morphine, 197, 219, 267, 311, 335, 197
  motor performance, 197
  naloxone, 43, 197
  naltrexone, 43, 267
  neonatal monosodium glutamate, 165
  noradrenergic receptors, 321
  operant behavior suppression, 235
  operant responding, 39
  opiate antagonist, 219
  opiate receptors, 219
  opiate withdrawal, 235
  phencyclidine, 489
  physostigmine, 375
  pigeons, 375
  pirenperone, 39
  place conditioning, 219
  seizure thresholds, 165
  SKF 10,047, 489
  stereotyped behavior, 489
  swimming-induced immobility, 321
  threshold determination, 311
Dynorphinergic mechanisms, 465
  exploratory behavior
  hippocampus
  inbred mice
  strain differences

Eating, 427
  benzodiazepines
  β-carbolines
  palatability
Electrical stimulation
  amphetamine, 251
  cue properties, 251, 261
  differential effects, 261
  discrimination, 261
  dopaminergic/non-dopaminergic substrates, 251
  haloperidol, 251
  physostigmine, 261
  ventral tegmentum, 251, 261
Electrode location, 291
  estradiol
  ovariectomy
  rats, females
  seizures, amygdala-kindled
Endogenous opioids, 95
  footshock
  hyperthermia
  thermoregulation
β-Endorphin, 197
  drug interaction
  lateral hypothalamus
  morphine
  motor performance
  naloxone
β-Endorphin concentrations, 385
  autotomy
  deafferentation
  Met-enkephalin concentrations
  strain differences
Met-Enkephalin concentrations, 385
  autotomy
  beta-endorphin concentrations
  deafferentation
  strain differences
Ephedrine, 361
  exercise enhancement
  human studies
  maximal aerobic capacity
  perceived exertion
  sympathomimetics
Escape behavior, 203
  delayed onset
  haloperidol
  learning
Escape failures, 321
  animal models
  antidepressant-like profiles
  drug interaction
  GABA agonists
  learned helplessness
  noradrenergic receptors
  swimming-induced immobility
Estradiol, 291
  electrode location
  ovariectomy
  rats, females
  seizures, amygdala-kindled
Ethanol
  alcohol preference, 105
  drinking, 437
  latent inhibition, 53, 57
  selective breeding, 105
  self-administration, 53, 57
  social structure, 437
  strain differences, 53
  stress, 437
  taste aversion learning, 53, 57
  tolerance persistence, 105
Ethylcholine aziridinium, 157
  acetylcholine concentration
  extinction
  learning and memory impairment
Ethylketocyclazocine
  behavioral analyses, 43
  drug interaction, 43, 489
  locomotor activity, 43
  naloxone, 43
  phencyclidine, 489
  SKF 10,047, 489
  stereotyped behavior, 489
Exercise enhancement, 361

ephedrine
human studies
maximal aerobic capacity
perceived exertion
sympathomimetics
Exploratory activity
barbiturates, 75
benzodiazepine receptor agonist, 75
drug interaction, 75
dynorphinergic mechanisms, 465
hippocampus, 465
inbred mice, 465
strain differences, 465
Extinction
acetylcholine concentration, 157
diazepam, 81
ethylcholine aziridinium, 157
learning and memory impairment, 157
monkeys, 81
self-administration, 81

Fighting, 341
age differences
individual housing
phencyclidine
Fluid diet, 87
abstinence
morphine
physical dependence
Flurothyl, 165
drug interaction
hypothermia
neonatal monosodium glutamate
seizure thresholds
Food intake, 71
hyperphagia
phenylpropanolamine
Footshock, 95
endogenous opioids
hyperthermia
thermoregulation
Free-choice consumption, 111
behavioral tolerance
chronic ethanol tolerance
selective breeding
Free recall, 347
diazepam
human studies
memory, explicit
memory, implicit
neurological impairment
spared memory function
word completion

GABA, 521
benzodiazepine receptor binding
in vivo
Tyr-MIF-1
GABA agonists, 321
animal models
antidepressant-like profiles
drug interaction
escape failures
learned helplessness
noradrenergic receptors
swimming-induced immobility
GABA mechanisms, 453
catalepsy
muscle rigidity
substantia nigra pars reticulata
GABA transaminase inhibitors, 47
locomotor activity
sexual behavior, male rat
Gastric ulcers, 419
basal gastric acid secretion
histidine carboxylase
intraluminal pH levels
Genetic variation, 317
diisopropylphosphofluoridate
inbred mice
paraoxonase activity

Hallucinogens, 327
2,5-dimethoxy-4-methylamphetamine
dose-dependent effects
intracranial administration
operant behavior
Haloperidol
amphetamine, 251
cue properties, 251
delayed onset, 203
dopaminergic/non-dopaminergic substrates, 251
electrical stimulation, 251
escape behavior, 203
learning, 203
oral movement, 175
tolerance, 175
treatment duration, 175
ventral tegmentum, 251
Hippocampal choline uptake, 433
intraseptal drug injection
pentobarbital-induced narcosis
Hippocampus, 465
dynorphinergic mechanisms
exploratory behavior
inbred mice
strain differences
Histidine carboxylase, 419
basal gastric acid secretion
gastric ulcer
intraluminal pH levels
Hormone
estradiol, 291
insulin, 447
progesterone, 371
5HT agonists, 1
drug discrimination
5HT receptors
tetrahydro-β-carboline
5HT receptors, 1
drug discrimination
5HT agonists
tetrahydro-β-carboline
5-HT_{1A} agonists, 187
benzodiazepines
hypertonic saline consumption
rehydration
Human studies
cigarette smoking, 305
cognitive behavior, 213
diazepam, 347
ephedrine, 361
exercise enhancement, 361
free recall, 347
maximal aerobic capacity, 361
memory, explicit, 347
memory, implicit, 347
methylphenidate, 213
neurological impairment, 347
nicotine intake, 305
perceived exertion, 361
problem solving, 213
spared memory function, 347
sympathomimetics, 361
tobacco smoke refining, 305
word completion, 347
Human studies, males, 349
cardiovascular responses
cocaine
drug interaction
marijuana
Hyperphagia, 71
food intake
phenylpropanolamine
Hyperthermia, 95
endogenous opioids
footshock
thermoregulation
Hypertonic saline consumption, 187
benzodiazepines
5-HT_{1A} agonists
rehydration
Hypothermia, 165
drug interaction
flurothyl
neonatal monosodium glutamate
seizure thresholds
Hypothyroidism, 193
dopamine receptor sensitivity
post-synaptic changes

Inbred mice
diisopropylphosphofluoridate, 317
dynorphinergic mechanisms, 465
exploratory behavior, 465
genetic variation, 465
hippocampus, 465
paraoxonase activity, 317
strain differences, 465
Individual housing, 341
age differences
fighting
phencyclidine
Injection speed, 407
cocaine
minimum reinforcing dose
monkeys, crab-eating
pentobarbital
self-administration
Insulin-induced drinking, 447
angiotensin II
plasma volume
Intracerebroventricular administration, 15
amino acids
barrel rotation
bradykinin analogs
neuropeptides
Intracranial administration, 327
2,5-dimethoxy-4-methylamphetamine
dose-dependent effects
hallucinogens
operant behavior
Intraluminal pH levels, 419
basal gastric acid secretion
gastric ulcers
histidine carboxylase
Intraseptal drug injection, 433
hippocampal choline uptake
pentobarbital-induced narcosis

Intravenous self-administration, 389
baboons
cocaine
phenylpropanolamine
Investigatory behavior, 393
amphetamine
apomorphine
dopamine neuronal firing
locomotor activity
In vivo, 521
benzodiazepine receptor binding
GABA
Tyr-MIF-1
In vivo voltammetry, 381
amphetamine
ascorbic acid
serotonin depletion
uric acid

Kappa receptors, 227
opiate aversions
place conditioning
Key-pecking behavior, 375
atropine
chronic administration
dose-dependent effects
drug interactions
physostigmine
pigeons

Latent inhibition
ethanol, 53, 57
self-administration, 53, 57
strain differences, 57
taste aversion learning, 53, 57
Lateral hypothalamus
conditioned place preference, 511
drug interaction, 197
β-endorphin, 197
morphine, 197
motor performance, 197
naloxone, 197
reinforcement, 511
substance P, 511
Learned helplessness, 321
animal models
antidepressant-like profiles
drug interaction
escape failures
GABA agonists
noradrenergic receptors
swimming-induced immobility
Learning, 203
delayed onset
escape behavior
haloperidol
Learning and memory impairment, 157
acetylcholine concentration
ethylcholine aziridinium
extinction
Light/dark test, 29
anxiogenic effects
locomotor activity
methyl-β-carboline-3-carboxylate
RO 15-1788
Locomotor activity
adenosine receptors, 179
animal model, 291
anxiogenic effects, 29
amphetamine, 393, 423
apomorphine, 393
behavioral analyses, 43
behavioral effects, 423
caffeine, 179
conditioned place preference, 267
dopamine neuronal firing, 393
drug interaction, 43, 393
ethylketocyclazocine, 43, 393
GABA transaminase inhibitors, 47
investigatory behavior, 393
light/dark test, 29
methyl-β-carboline-3-carboxylate, 29
morphine, 267
MPTP pretreatment, 291
naloxone, 43
naltrexone, 267
nicotine, 291
Parkinson's disease, 291
L-phenylisopropyladenosine, 179
RO 15, 1788, 29
sexual behavior, male rat, 47
strain differences, 179
stereotypy, 423

Marijuana, 459
cardiovascular responses
cocaine
drug interaction
human studies, males
Maximal aerobic capacity, 361
ephedrine
exercise enhancement
human studies
perceived exertion
sympathomimetics
MDA, 39
drug interactions
MDMA
operant responding
pirenperone
MDMA, 39
drug interactions
MDA
operant responding
pirenperone
Medial hypothalamus, 21
benzodiazepine receptors
brain stimulation
Memory, 353
passive avoidance retention
serotonergic antagonists
Memory, explicit, 347
diazepam
free recall
human studies
memory, implicit
neurological impairment
spared memory function
word completion
Memory impairment, 243
animal model for dementia
cerebral embolism
discrimination task
Memory, implicit, 347
diazepam
free recall
human studies
memory, explicit
neurological impairment
spared memory function
word completion

Mephenytoin, 483
dose-dependent effects
methsuximide
pigeons
repeated acquisition
Methsuximide, 483
dose-dependent effects
mephenytoin
pigeons
repeated acquisition
Methyl-β-carboline-3-carboxylate, 29
anxiogenic effects
light/dark test
locomotor activity
RO 15-1788
Methylphenidate, 213
cognitive behavior
human studies
problem solving
Methylxanthines, 235
drug interaction
operant behavior
opiate withdrawal
Minimum reinforcing dose, 407
cocaine
injection speed
monkeys, crab-eating
pentobarbital
self-administration
Monkeys
aggression, 503
diazepam, 81
dose-dependent effects, 503
extinction, 81
self-administration, 81
tryptophan, 503
Monkeys, crab-eating, 407
cocaine
injection speed
minimum reinforcing dose
pentobarbital
self-administration
Morphine
abstinence, 87
amphetamine, 335
d-amphetamine, 311
brain stimulation reward, 311
central cholinergic mechanisms, 335
conditioned place preference, 267
conditioned taste aversion, 219, 335
differential involvement, 335
drug interactions, 197, 219, 267, 311
β-endorphin, 197
fluid diet, 87
lateral hypothalamus, 197
locomotor activity, 267
morphine, 335
motor performance, 197
naloxone, 197
naltrexone, 267
opiate antagonist, 219
opiate receptors, 219
physical dependence, 87
place conditioning, 219
threshold determination, 311
Motor performance, 197
drug interaction
β-endorphin
lateral hypothalamus
morphine
naloxone
Motor responses, 275

arecoline
autoimmunity
dose-dependent effects
nicotine
strain differences
MPTP pretreatment, 291
animal model
locomotor activity
nicotine
Parkinson's disease
Muricide, 101
neuropeptide Y
noradrenaline
olfactory bulbectomy
Muscle rigidity, 453
catalepsy
GABA mechanisms
substantia nigra pars reticulata

NaCl intake, 209
repeated administration
reserpine
tolerance
Naloxone
behavioral analyses, 43
drug interaction, 43, 197
β-endorphin, 197
ethylketocyclazocine, 43
lateral hypothalamus, 197
morphine, 197
motor performance, 197
Naltrexone, 267
conditioned place preference
drug interaction
locomotor activity
morphine
Neonatal exposure, 367
depressive behavior
desipramine
zimeldine
Neonatal monosodium glutamate, 165
drug interaction
flurothyl
hypothermia
seizure thresholds
N-ethyl-3,4-methylenedioxyamphetamine, 153
behavioral effects
dose-dependent effects
drug comparisons
Neuroleptics, 283
alpha-2 agonists
CNS depressants
opioid antagonists
opioid-induced rigidity
reversal effects
route of administration
Neurological impairment, 347
diazepam
free recall
human studies
memory, explicit
memory, implicit
spared memory function
word completion
Neuropeptide Y
muricide
noradrenaline
olfactory bulbectomy
Neuropeptides, 15
amino acids
barrel rotation
bradykinin analogs
intracerebroventricular administration
Nicotine
animal model, 291
arecoline, 275
autoimmunity, 275
conditioned taste aversion, 495
dose-dependent effects, 275
locomotor activity, 291
motor responses, 275
MPTP pretreatment, 291
Parkinson's disease, 291
route of administration, 495
saccharin, 495
strain differences, 275
Nicotine intake, 305
cigarette smoking
human studies
tobacco smoke refining
Nitrous oxide, 7
classical conditioning
skin conductance
Noise, 147
acute exposure
central nervous system
choline uptake
Noradrenaline, 101
muricide
neuropeptide Y
olfactory bulbectomy
Noradrenergic receptors, 321
animal models
antidepressant-like profiles
drug interaction
escape failures
GABA agonists
learned helplessness
swimming-induced immobility

Olfactory bulbectomy, 101
muricide
neuropeptide Y
noradrenaline
Operant behavior, 327
2,5-dimethoxy-4-methylamphetamine
dose-dependent effects
hallucinogens
intracranial administration
Operant behavior suppression, 235
drug interaction
methylxanthines
opiate withdrawal
Operant responding, 39
drug interactions
MDA
MDMA
pirenperone
Opiate antagonist, 219
conditioned taste aversion
drug interaction
morphine
opiate receptors
place conditioning
Opiate aversions, 227
kappa receptors
opiate aversions
Opiate receptors, 219
conditioned taste aversion
drug interaction
morphine
opiate antagonist
place conditioning
Opiate withdrawal, 235
drug interaction
methylxanthines
operant behavior suppression
Opioid antagonists, 283
alpha-2 agonists
CNS depressants
neuroleptics
opioid-induced rigidity
reversal effects
route of administration
Opioid-induced rigidity, 283
alpha-2 agonists
CNS depressants
neuroleptics
opioid antagonists
reversal effects
route of administration
Oral movement, 175
haloperidol
tolerance
treatment duration
Oral self-administration, 517
chronic excessive intake
cocaine
schedule induction
Ovariectomy, 291
electrode location
estradiol
rats, females
seizures, amygdala-kindled

Palatability, 427
benzodiazepines
β-carbolines
eating
Paraoxonase activity, 317
diisopropylphosphofluoridate
genetic variation
inbred mice
Parkinson's disease, 291
animal model
locomotor activity
MPTP pretreatment
nicotine
Passive avoidance retention, 353
memory
serotonergic antagonists
Pentobarbital
behavioral hyperactivity, 469
cerebral glucose metabolism, 469
choline supplementation, 369
chronic administration, 469
cocaine, 407
drug discrimination, 371
injection speed, 407
minimum reinforcing dose, 407
monkeys, crab-eating, 407
progesterone stimulus properties, 371
self-administration, 407
sex differences, 371
Pentobarbital-induced narcosis, 433
hippocampal choline uptake
intraseptal drug injection
Peptide
angiotensin II, 447
bradykinin, 15
β-endorphin, 197, 385
Met-enkephalin, 385

neuropeptide Y, 101
substance P, 511
Perceived exertion, 361
ephedrine
exercise enhancement
human studies
maximal aerobic capacity
sympathomimetics
Perinatal phencyclidine, 411
behavioral development
developmental toxicity
prenatal phencyclidine
Phencyclidine
age differences, 341
drug interactions, 489
ethylketocyclazocine, 489
fighting, 341
individual housing, 341
SKF 10,047, 489
stereotyped behavior, 489
L-Phenylisopropyladenosine, 179
adenosine receptors
caffeine
locomotor activity
strain differences
Phenylpropanolamine
baboons, 389
cocaine substitution procedure, 389
food intake, 71
hyperphagia, 71
intravenous self-administration, 389
Physical dependence, 87
abstinence
fluid diet
morphine
Physostigmine
atropine, 375
chronic administration, 375
cue properties, 261
differential effects, 261
discrimination, 261
dose-dependent effects, 375
drug interactions, 375
electrical stimulation, 261
key-pecking behavior, 375
pigeons, 375
ventral tegmentum, 261
Pigeons
atropine, 375
chronic administration, 375
dose-dependent effects, 375, 483
drug interactions, 375
key-pecking behavior, 375
mephenytoin, 483
methsuximide, 483
physostigmine, 375
repeated acquisition, 483
Pirenperone, 39
drug interactions
MDA
MDMA
operant responding
Place conditioning
conditioned taste aversion, 219
drug interaction, 219
kappa receptors, 227
morphine, 219
opiate antagonist, 219
opiate aversions, 227
opiate receptors, 219
Plasma corticosterone levels, 443
progabide
stress, ether
Plasma volume, 447
angiotensin II
insulin induced drinking
Post-synaptic changes, 193
dopamine receptor sensitivity
hypothyroidism
Prenatal development, 411
behavioral development
developmental toxicity
perinatal toxicity
Problem solving, 213
cognitive behavior
human studies
methylphenidate
Progabide, 443
plasma corticosterone levels
stress, ether
Progesterone stimulus properties, 371
drug discrimination
pentobarbital

Rats, females, 291
electrode location
estradiol
ovariectomy
seizures, amygdala-kindled
Rehydration, 187
benzodiazepines
5-HT agonists
hypertonic saline consumption
Reinforcement, 511
conditioned place preference
lateral hypothalamus
substance P
Repeated acquisition, 483
dose-dependent effects
mephenytoin
methsuximide
pigeons
Repeated administration, 209
NaCl intake
reserpine
tolerance
Reserpine, 209
NaCl intake
repeated administration
tolerance
Reversal effects, 283
alpha-2 agonists
CNS depressants
neuroleptics
opioid antagonists
opioid-induced rigidity
route of administration
RO 15-1788, 29
anxiogenic effects
light/dark test
locomotor activity
methyl-β-carboline-3-carboxylate
Route of administration
alpha-2 agonists, 283
capsaicin, 65
CNS depressants, 283
conditioned taste aversion, 495
neuroleptics, 283
nicotine, 495
opioid antagonists, 283
opioid-induced rigidity, 283
reversal effects, 283
saccharin, 495
substance P release, 65
thermoregulation, 65
Tween 80, 65

Saccharin, 495
conditioned taste aversion
nicotine
route of administration
Schedule induction, 517
chronic excessive intake
cocaine
oral self-administration
Seizure thresholds, 165
drug interaction
flurothyl
hypothermia
neonatal monosodium glutamate
Seizures, amygdala-kindled
electrode location
estradiol
ovariectomy
rats, females
Selective breeding
alcohol preference, 105
behavioral tolerance, 111
chronic ethanol tolerance, 111
ethanol, 105
free-choice consumption, 111
tolerance persistence, 105
Self-administration
cocaine, 407
diazepam, 81
ethanol, 53, 57
extinction, 81
injection speed, 407
latent inhibition, 53, 57
minimum reinforcing dose, 407
monkeys, 81
monkeys, crab-eating, 407
pentobarbital, 407
strain differences, 57
taste aversion learning, 53, 57
Serotonergic antagonists, 353
memory
passive avoidance retention
sex differences
Serotonin depletion, 381
amphetamine
ascorbic acid
in vivo voltammetry
uric acid
Sex differences, 371
drug discrimination
pentobarbital
progesterone
Sexual behavior, male rat
GABA transaminase inhibitors
locomotor activity
SKF 10,047
drug interactions
ethylketocyclazocine
phencyclidine
stereotyped behavior
Skin conductance, 7
classical conditioning
nitrous oxide
Social structure, 437
drinking
ethanol
stress
Spared memory function, 347

diazepam
free recall
human studies
memory, explicit
memory, implicit
neurological impairment
word completion
Stereotypy
amphetamine, 423
apomorphine, 477
behavioral effects, 423
D1 binding sites, 477
D2 binding sites, 477
drug interactions, 489
ethylketocyclazocine, 489
locomotor activity, 423
phencyclidine, 489
SKF 10,047, 489
up-regulation, 477
Strain differences
adenosine receptors, 179
arecoline, 275
autoimmunity, 275
autotomy, 385
caffeine, 179
deafferentation, 385
dose-dependent effects, 275
dynorphinergic mechanisms, 465
beta-endorphin concentrations, 385
Met-enkephalin concentrations, 385
ethanol, 57
exploratory behavior, 465
hippocampus, 465
inbred mice, 465
latent inhibition, 57
locomotor activity, 179
motor responses, 275
nicotine, 275
L-phenylisopropyladenosine, 179
self-administration, 57
taste aversion learning, 57
Stress, 437
drinking
ethanol
social structure
Stress, ether, 443
plasma corticosterone levels
progabide
Substance P, 511
conditioned place preference
lateral hypothalamus
reinforcement
Substance P release, 65
capsaicin
route of administration
thermoregulation
Tween 80
Substantia nigra pars reticulata, 453
catalepsy
GABA mechanisms
muscle rigidity
Swimming-induced immobility, 321
animal models
antidepressant-like profiles
drug interaction
escape failures
GABA agonists
learned helplessness
noradrenergic receptors
Sympathomimetics, 361
ephedrine
exercise enhancement
human studies
maximal aerobic capacity
perceived exertion

Taste aversion learning
ethanol, 53, 57
latent inhibition, 53, 57
self-administration, 53, 57
strain differences
Δ^9-Tetrahydrocannabinol, 171
beta-adrenoceptors
cardiovascular effects
chronic treatment
Tetrahydro-β-carboline, 1
drug discrimination
5HT agonists
5HT receptors
Thermoregulation
capsaicin, 65
endogenous opioids, 95
footshock, 95
hyperthermia, 95
route of administration, 65
substance P, 65
Tween 80, 65
Threshold determination, 311
d-amphetamine
brain stimulation reward
drug interactions
morphine
Tobacco smoke refining, 305
cigarette smoking
human studies
nicotine intake
Tolerance
central mechanism, 401
chronic administration, 401
cocaine, 401
discriminative stimulus properties, 401
haloperidol, 175
NaCl intake, 209
oral movement, 175
repeated administration, 209
reserpine, 209
treatment duration, 175
Tolerance persistence, 105
alcohol preference
ethanol
selective breeding
Treatment duration, 175
haloperidol
oral movement
tolerance
Tryptophan, 503
aggression
dose-dependent
monkeys
Tween 80, 65
capsaicin
route of administration
substance P release
thermoregulation
Tyr-MIF-1, 521
benzodiazepine receptor binding
GABA
in vivo

Up-regulation, 477
apomorphine
D1 binding sites
D2 binding sites
stereotypy
Uric acid, 381
amphetamine
ascorbic acid
in vivo voltammetry
serotonin depletion
uric acid

Ventral tegmentum
amphetamine, 251
cue properties, 251, 261
differential effects, 261
discrimination, 261
dopaminergic/non-dopaminergic substrates, 251
electrical stimulation, 251, 261
haloperidol, 251
physostigmine, 261

Word completion, 347
diazepam
free recall
human studies
memory, explicit
memory, implicit
neurological impairment
spared memory function

Zimeldine, 367
depressive behavior
desipramine
neonatal exposure

AUTHOR INDEX

Agmo, A., 47
Ali, S. F., 171
Altman, H. J., 353
Amit, Z., 335
Bain, G. T., 311
Bardo, M. T., 267
Bartness, T. J., 447
Bechara, A., 219, 227
Behm, F., 305
Belzung, C., 29
Benvenga, M. J., 283
Bianchi, M., 385
Bierkamper, G., 165
Blaker, W. D., 157
Blanchard, D. C., 437
Blanchard, R. J., 437

Block, R. I., 7
Boja, J. W., 153
Boucke, K., 511
Branch, M. N., 375
Breese, G. R., 213
Brini, A., 385
Buckholtz, N. S., 179
Buterbaugh, G. G., 291

Calkins, D., 433
Cameron, D. L., 193
Cannon, D. S. 53, 57
Capacchione, J. F., 283
Carey, R. J., 203
Carrell, L. E., 53, 57
Caton, T. M., 495
Cawley, G., 469
Chamberlain, B., 503
Chapouthier, G., 29
Chipkin, R. E., 477
Cools, A., 453
Cooper, S. J., 187, 427
Crocker, A. D., 193

Danti, S., 321
Dawson, R., Jr., 165
De Kok, Y. J. M., 465
Delaney, D., 483
DeMeersman, R., 361
Desa, A., 187
Dib, B., 65
Divine, K. K., 495
Dodd, R. H., 29
Druhan, J. P., 251, 261

Eckerman, D. A., 213
Ellison, G. D., 175
Emmett-Oglesby, M. W., 401
Eriksson, P. S., 87
Ervin, F. R., 503
Etscorn, F., 495
Evans, E. B., 171

Falk, J. L., 209, 517
Fang, J. C., 347
Fernández, H., 47
Fibiger, H. C., 251, 261
Fischman, M. W., 459
Foltin, R. W., 459
Forster, M. J., 275
Fowles, D. C., 7
Fujiwara, M., 101
Furukawa, H., 411, 489

Gatto, G. J., 105, 111
Geiger, J. D., 419
Getty, D., 361
Geyer, M. A., 393
Ghoneim, M. M., 7, 347
Glennon, R. A., 39
Goodwin, S. D., 157
Graeff, F. G., 21
Grant, K. A., 81
Greenblatt, D. J., 521
Griffiths, R. R., 389
Gualtieri, C. T., 213

Hagen, L. S., 495
Harper, A. E., 525
Hashim, A., 299
Haskett, C., 381
Heinsbroek, R. P. W., 371
Hilakivi, I., 367
Hilakivi, L. A., 367
Hinrichs, J. V., 347
Hiramatsu, M., 411, 489
Holzhäuer-Oitzl, M.-S., 511
Hori, K., 437
Horita, A., 433
Hubner, C. B., 311
Hunt, T., 335
Huston, J. P., 511

Iorio, L. C., 477
Ishikawa, K., 411
Itoh, T., 35

Jenks, B. G., 465
Jerussi, T. P., 283
Johanson, C. E., 81

Kafiluddi, R., 171
Kameyama, T., 43, 411, 489
Kastin, A. J., 521
Kataoka, Y., 101
Kato, S., 407
Kennedy, R. H., 171
Kenney, S., 203
Kiyota, Y., 243
Kleven, M. S., 235
Kohori, I., 35
Kolasiewicz, W., 453
Kornetsky, C., 311
Kuczenski, R., 393
Kumar, V., 7
Kuribara, H., 209

Lai, H., 147, 433
Lajtha, A., 299
Lal, H., 275
Lamb, R. J., 389
Li, T.-K., 105, 111
Lister, R. G., 75
Lumeng, L., 105, 111

McBride, W. J., 105, 111
McQuade, R. D., 477
Manev, H., 443
Mann-Koepke, K., 213
Mantegazza, P., 385
Martin, P., 321
Martin-Iverson, M. T., 251, 261
Masuda, Y., 35
Middaugh, L. D., 179
Milani, H., 21
Miller, L. G., 521
Mine, K., 101
Misslin, R., 29
Miyamoto, M., 243
Mokler, D. J., 327
Moore, G. A., 495
Morgan, M. J., 95
Moya-Huff, F. A., 71
Mueller, K., 381
Murai, S., 35
Murphy, J. M., 105, 111
Murphy-Erdosh, C., 317
Muscat, R., 423

Nabeshima, T., 411, 489
Nagaoka, A., 243
Neisewander, J. L., 267
Niwa, M., 101
Normile, H. J., 353

Ossowska, K., 453

Panerai, A. E., 385
Paredes, R., 47
Pathak, D., 7
Paule, M. G., 171
Pearlson, G. D., 459
Pechnick, R. N., 95
Pedroso, J. J., 459
Pericic, D., 443
Perry, D. C., 15
Phillips, A. G., 251, 261
Pihl, R. O., 503
Poling, A., 483
Poncelet, M., 321

Rech, R. H., 327
Repa, J. J., 525
Retz, K. C., 275, 401
Rönnback, L., 87
Rose, J. E., 305
Rosecrans, J. A., 39
Rosengren, L., 87
Rothermel, S., 469
Russo, P. V., 393

Sacerdote, P., 385
Saito, H., 35
Sakurai, Y., 101
Sanders, D. L., 495
Sannerud, C. A., 389
Sant, W. W., 175
Scallet, A. C., 171
Schaal, D. W., 375
Schaefer, D. C., 361
Schechter, M. D., 1, 153
Schroeder, S. R., 213
Scott, E. P., 495
See, R. E., 175
Segal, D. S., 393
Segal, R., 335
Seifen, E., 171
Sershen, H., 299
Sherman, L. C., 327
Simon, P., 321
Slikker, W., Jr., 171
Smolen, A., 317
Smolen, T. N., 317
Soubrié, P., 321
Sparber, S. B., 235
Spoerlein, M. T., 341
Stoudt, K. W., 327

Tang, M., 209, 517
Tews, J. K., 525
Tom, P., 437
Towell, A., 423
Trimmer, C. K., 275

Ueki, S., 101
Ukai, M., 43

Van Abeelen, J. H. F., 465
Van Daal, J. H. H. M., 465
van de Poll, N. E., 371
Van Der Kooy, D., 219, 227
van Haaren, F., 371
VanderWende, C., 341
Vogel, E., 29

Wakasa, Y., 407
Waldbillig, R. J., 447
Waller, M. B., 105, 111
Wecker, L., 469
Wehner, J. M., 317
Wendelaar Bonga, S. E., 465
Westerberg, V. S., 419
Wilkie, D. M., 251, 261
Willner, P., 423
Willis, G. L., 197
Wilmot, C. A., 341
Wolfarth, S., 453
Wood, D. M., 401
Wronski, A., 87

Yamaguchi, K., 411
Yamashita, K., 101
Yanagita, T., 407
Yerbury, R. E., 427
Young, S. N., 503

Zabawska, J., 433
Zantvoord, F., 371
Zeuchner, J., 87
Zito, K. A., 219
Zucker, J., 433